Han-Joo Kim, PhD is the CEO and co-founder of IMNEWRUN, where he leads the company’s strategic direction, platform innovation, and the development of transformative therapeutics for brain health. Over the past two decades, Dr. Kim has built a distinguished career at the intersection of biotechnology, pharmaceuticals, and translational science—bringing together scientific insight, analytical rigor, and business acumen. He has led initiatives spanning early discovery to late-stage development, including regulatory strategy, clinical trial design, and global deal-making.

Before founding IMNEWRUN in 2019, Dr. Kim held leadership roles at Yuhan Corporation, where he directed R&D strategy, business development, and biostatistics. His work played a pivotal role in the development of Lazertinib—from clinical trial design to global partnering—culminating in its landmark licensing agreement with Johnson & Johnson. He also led multiple global collaborations, including joint ventures and licensing deals with companies such as Boehringer Ingelheim and Gilead Sciences, shaping Yuhan’s global innovation portfolio.

Earlier in his career, Dr. Kim served as a lead statistical scientist at global pharmaceutical companies including Forest Laboratories (now Allergan), Novartis, and Eisai. He was instrumental in advancing data-driven strategies in oncology and respiratory drug development, pioneering the use of modern trial designs and model-based analytics.

Dr. Kim earned his B.S. in Statistics from The George Washington University and received his M.S. and Ph.D. in Biostatistics from the University of Pennsylvania School of Medicine.